Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
Gini F. Fleming(University of Chicago Medical Center), James V. Fiorica(Moffitt Cancer Center), Julia Chapman(University of Kansas Medical Center), Michael W. Sill(University at Buffalo, State University of New York), Kathleen M. Darcy(Gynecologic Oncology Group), D. Scott McMeekin(University of Oklahoma), Ira Horowitz(Gynecologic Oncology Group), Lisa Adler(University of Colorado Health), Jonathan S. Berek(Stanford Health Care), J.T. Thigpen(Nova Southeastern University), Paul DiSilvestro(Women & Infants Hospital of Rhode Island)
Cited by 297
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Revised FIGO staging for carcinoma of the cervix uteri
|International Journal of Gynecology & Obstetrics|2019|1k